1007 related articles for article (PubMed ID: 27922681)
1. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
3. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
4. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
6. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
7. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
8. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
9. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
11. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
13. mir-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance.
Li J; Guan J; Long X; Wang Y; Xiang X
Oncol Rep; 2016 Jun; 35(6):3523-31. PubMed ID: 27035564
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
16. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
17. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer.
Liu CL; Chen SF; Wu MZ; Jao SW; Lin YS; Yang CY; Lee TY; Wen LW; Lan GL; Nieh S
Oncotarget; 2016 Mar; 7(12):14279-90. PubMed ID: 26872057
[TBL] [Abstract][Full Text] [Related]
18. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
19. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Lu W; Zuo Y; Feng Y; Zhang M
Tumour Biol; 2014 Nov; 35(11):10699-705. PubMed ID: 25070488
[TBL] [Abstract][Full Text] [Related]
20. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]